

## **Freedom of Information Request: Our Reference CTMUHB\_316\_22**

### **You asked:**

Q1. In the past 3 months (or the latest 3 months data you have available), how many melanoma patients were treated with:

- Bevacizumab (Avastin)
- Dacarbazine (DTIC)
- Trametinib (Mekinist)
- Dabrafenib (Tafinlar)
- Ipilimumab (Yervoy)
- Vemurafenib (Zelboraf)
- Nivolumab (Opdivo)
- Nivolumab + Ipilimumab (Opdivo + Yervoy)
- Pembrolizumab (Keytruda)
- Vemurafenib + cobimetinib (Zelboraf + Cotellic)
- Dabrafenib + Trametinib (Tafinlar + Mekinist)
- Braftovi (encorafenib) in combination with Mektovi (binimetinib) for BRAF V600 patients
- Other active systemic anti-cancer therapy [please state]
- Palliative care only

Q2. In the past 3 months (or the latest 3 months data you have available), how many metastatic melanoma patients were treated with the following:

- Ipilimumab
- Ipilimumab AND Nivolumab
- Nivolumab
- Pembrolizumab
- Dabrafenib AND Trametinib
- Any Other Targeted Therapy (Dabrafenib /Encorafenib AND Binimetinib /Trametinib /Vemurafenib /Vemurafenib AND Cobimetinib)
- Other active systemic anti-cancer therapy

- Palliative care only

**Our response:**

We can confirm that Cwm Taf Morgannwg University Health Board does not hold the information you require. The Health Board does not administer the treatments listed. Cwm Taf Morgannwg residents receive melanoma cancer treatments from the Velindre Cancer Centre or Singleton Hospital (Oncology) based on their postcode. Therefore, you will need to redirect your request to Velindre/Singleton, who provide these services to Cwm Taf Morgannwg residents.

Contact details are shown below in the following links:

For Velindre:

[Freedom of information contacts - Velindre University NHS Trust](#)

For Singleton Hospital – Swansea Bay University Health Board:

[Freedom of information - Swansea Bay University Health Board \(nhs.wales\)](#)